Back to Authors

Sechi, Elia

0000-0003-4698-663X

Mayo Clinic

Departments of Neurology and Center for MS and Autoimmune Neurology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.

Citations 29

Neurologic autoimmunity and immune checkpoint inhibitors

Neurology | August 14, 2020 | Volume: 95 | Issue: 17 | Pages: No page available

10.1212/wnl.0000000000010632 | PMID 32796130

Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions

Multiple Sclerosis Journal | July 15, 2020 | Volume: 27 | Issue: 6 | Pages: 895-902

10.1177/1352458520940983 | PMID 32667237

Objective: To compare progressive motor impairment onset attributable to a “critical” central nervous system (CNS) demyelinating lesion in patients with highly restricted versus unlimited magnetic resonance imaging (MRI) lesion burden. Methods: We identified 135 patients with progressive motor impairment for ⩾1 year attributable to a “critical” demyelinating lesion with: MRI burden of 1 lesion (“progressive solitary sclerosis”), 2–5 lesions (“progressive paucisclerosis”), or unrestricted (>5) lesions and “progressive unilateral hemiparesis.” Neuroradiology review of brain and spinal cord MRI documented unequivocally demyelinating lesions. Results: A total of 33 (24.4%) patients had progressive solitary sclerosis; 56 (41.5%) patients had progressive paucisclerosis; and 46 (34.1%) patients had progressive unilateral hemiparesis. Median age at onset of progressive motor impairment was younger in progressive solitary sclerosis (49 years; range 24–73) and progressive paucisclerosis (50 years; range 30–64) than in progressive unilateral hemiparesis (54 years; range 39–77; p = 0.02 and p = 0.003, respectively). Within progressive unilateral hemiparesis, motor-progression onset was similar between those with 4–10, 11–20, or >20 brain lesions (55, 54, 53 years of age, respectively; p = 0.44). Conclusion: Motor-progression age is similar, but paradoxically earlier, in cohorts with highly restricted CNS lesion burden than in those with unrestricted lesion burden with progressive unilateral hemiparetic MS. The “critical” demyelinating lesion rather than total brain MRI lesion burden is the major contributor to motor-progression onset in these cohorts.
Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study

Multiple Sclerosis Journal | June 18, 2020 | Volume: 27 | Issue: 5 | Pages: 667-673

10.1177/1352458520929192 | PMID 32552535

Background: Progressive motor impairment anatomically attributable to prominent, focally atrophic lateral column spinal cord lesions (“critical lesions”) can be seen in multiple sclerosis (MS), for example, progressive hemiparetic MS. Objective: The aim of this study was to investigate whether similar spinal cord lesions are more frequent in long-standing MS patients with secondary progressive motor impairment (secondary progressive MS (SPMS)) versus those maintaining a relapsing-remitting course (relapsing-remitting MS (RRMS)). Methods: We retrospectively identified Olmsted County (MN, USA) residents on 31 December 2011 with (1) RRMS or SPMS for ⩾25 years, and (2) available brain and spine magnetic resonance imaging (MRI). A blinded neuroradiologist determined demyelinating lesion burden and presence of potential critical lesions (prominent focally atrophic spinal cord lateral column lesions). Results: In total, 32 patients were included: RRMS, 18; SPMS, 14. Median (range) disease duration (34 (27–53) vs. 39 (29–47) years) and relapse number (4 (1–10) vs. 3 (1–15)) were similar. In comparison to RRMS, SPMS patients more commonly showed potential critical spinal cord lesions (8/18 (44%) vs. 14/14 (100%)), higher spinal cord (median (range) 4 (1–7) vs. 7.5 (3–12)), and brain infratentorial (median (range) 1 (0–12) vs. 2.5 (1–13)) lesion number; p < 0.05. By multivariate analysis, only the presence of potential critical lesions independently associated with motor progression ( p = 0.02). Conclusion: Critical spinal cord lesions may be important contributors to motor progression in MS.
Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies

Multiple Sclerosis Journal | February 27, 2020 | Volume: 27 | Issue: 2 | Pages: 303-308

10.1177/1352458520907900 | PMID 32103708

Background: Myelitis accompanied by a negative spinal cord MRI may lead to diagnostic uncertainty. Objective and Methods: We retrospectively investigated the frequency of negative spinal cord MRI (performed <6 weeks from onset) in Mayo Clinic patients with myelin oligodendrocyte glycoprotein (MOG)-IgG-associated myelitis (2000–2019). Results: The initial spinal cord MRI was negative in 7/73 (10%) patients, despite severe acute disability (median EDSS, 7 (range, 4.5–8)); myelitis symptoms/signs were frequent (paraparesis, neurogenic bladder, sensory level, Lhermitte’s phenomenon). Myelitis lesions became overt at follow-up MRI in three patients. Conclusions: A negative spinal cord MRI should not dissuade from MOG-IgG testing in patients with acute/subacute myelitis.
Unilateral motor progression in MS

Neurology | July 10, 2019 | Volume: 93 | Issue: 7 | Pages: No page available

10.1212/wnl.0000000000007944 | PMID 31289142

Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology

Neurology | June 25, 2019 | Volume: 93 | Issue: 4 | Pages: No page available

10.1212/wnl.0000000000007828 | PMID 31235660

Hypertrophic olivary degeneration mimics relapse in neuromyelitis optica spectrum disorder

Neurology | February 12, 2019 | Volume: 92 | Issue: 7 | Pages: 343-344

10.1212/wnl.0000000000006930 | PMID 30745445

Area postrema syndrome in autoimmune GFAP astrocytopathy

Multiple Sclerosis Journal | January 21, 2019 | Volume: 26 | Issue: 2 | Pages: 255-256

10.1177/1352458519826489 | PMID 30663500

Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody

JAMA Neurology | December 21, 2018 | Volume: 76 | Issue: 3 | Pages: 301

10.1001/jamaneurol.2018.4053 | PMID 30575890